DK2806028T3 - RELATIONS AND PROCEDURES FOR REDUCING RECRUITMENT OR MIGRATION OF POLYMORPHNUCLEAR CELLS - Google Patents
RELATIONS AND PROCEDURES FOR REDUCING RECRUITMENT OR MIGRATION OF POLYMORPHNUCLEAR CELLS Download PDFInfo
- Publication number
- DK2806028T3 DK2806028T3 DK14154643.2T DK14154643T DK2806028T3 DK 2806028 T3 DK2806028 T3 DK 2806028T3 DK 14154643 T DK14154643 T DK 14154643T DK 2806028 T3 DK2806028 T3 DK 2806028T3
- Authority
- DK
- Denmark
- Prior art keywords
- cells
- pmn
- use according
- administered
- pharmaceutical composition
- Prior art date
Links
- 230000005012 migration Effects 0.000 title claims description 29
- 238000013508 migration Methods 0.000 title claims description 29
- 230000001603 reducing effect Effects 0.000 title claims description 23
- 230000007115 recruitment Effects 0.000 title claims description 18
- 238000000034 method Methods 0.000 title description 27
- 108091034117 Oligonucleotide Proteins 0.000 claims description 78
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 claims description 71
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 claims description 71
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 claims description 41
- 101100236208 Homo sapiens LTB4R gene Proteins 0.000 claims description 41
- 108010018951 Interleukin-8B Receptors Proteins 0.000 claims description 41
- 102100033374 Leukotriene B4 receptor 1 Human genes 0.000 claims description 41
- 230000004054 inflammatory process Effects 0.000 claims description 38
- 206010061218 Inflammation Diseases 0.000 claims description 36
- 238000011282 treatment Methods 0.000 claims description 29
- 230000017531 blood circulation Effects 0.000 claims description 22
- 210000000056 organ Anatomy 0.000 claims description 18
- 208000005189 Embolism Diseases 0.000 claims description 13
- 238000001727 in vivo Methods 0.000 claims description 13
- 208000014674 injury Diseases 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 230000000968 intestinal effect Effects 0.000 claims description 10
- 230000003247 decreasing effect Effects 0.000 claims description 9
- 230000003828 downregulation Effects 0.000 claims description 8
- 208000027866 inflammatory disease Diseases 0.000 claims description 7
- 238000007912 intraperitoneal administration Methods 0.000 claims description 7
- 208000010125 myocardial infarction Diseases 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 238000007920 subcutaneous administration Methods 0.000 claims description 7
- 238000002054 transplantation Methods 0.000 claims description 7
- 230000008733 trauma Effects 0.000 claims description 5
- 239000003527 fibrinolytic agent Substances 0.000 claims description 4
- 230000004048 modification Effects 0.000 claims description 4
- 238000012986 modification Methods 0.000 claims description 4
- 238000011477 surgical intervention Methods 0.000 claims description 4
- 229960000103 thrombolytic agent Drugs 0.000 claims description 4
- 238000002513 implantation Methods 0.000 claims description 3
- 238000011065 in-situ storage Methods 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 230000003292 diminished effect Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 129
- 150000001875 compounds Chemical class 0.000 description 79
- 241001465754 Metazoa Species 0.000 description 58
- 230000014509 gene expression Effects 0.000 description 58
- 239000002953 phosphate buffered saline Substances 0.000 description 46
- 230000009467 reduction Effects 0.000 description 41
- 101100437750 Schizosaccharomyces pombe (strain 972 / ATCC 24843) blt1 gene Proteins 0.000 description 37
- 210000004369 blood Anatomy 0.000 description 34
- 239000008280 blood Substances 0.000 description 34
- 241000699670 Mus sp. Species 0.000 description 33
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 33
- 238000012360 testing method Methods 0.000 description 33
- 241000700159 Rattus Species 0.000 description 30
- 230000000302 ischemic effect Effects 0.000 description 29
- 230000000694 effects Effects 0.000 description 28
- 239000000126 substance Substances 0.000 description 27
- 210000002216 heart Anatomy 0.000 description 26
- 210000000440 neutrophil Anatomy 0.000 description 26
- 230000010410 reperfusion Effects 0.000 description 26
- 238000002474 experimental method Methods 0.000 description 25
- 210000001519 tissue Anatomy 0.000 description 25
- 208000028867 ischemia Diseases 0.000 description 24
- 230000006378 damage Effects 0.000 description 22
- 108090001007 Interleukin-8 Proteins 0.000 description 19
- 102000004890 Interleukin-8 Human genes 0.000 description 19
- 210000000265 leukocyte Anatomy 0.000 description 19
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 18
- 108010003541 Platelet Activating Factor Proteins 0.000 description 18
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 17
- 230000006698 induction Effects 0.000 description 17
- 230000000638 stimulation Effects 0.000 description 17
- 206010061216 Infarction Diseases 0.000 description 16
- 208000006673 asthma Diseases 0.000 description 16
- 210000004556 brain Anatomy 0.000 description 16
- 230000007574 infarction Effects 0.000 description 16
- 230000002829 reductive effect Effects 0.000 description 16
- 102000003896 Myeloperoxidases Human genes 0.000 description 15
- 108090000235 Myeloperoxidases Proteins 0.000 description 15
- 238000000684 flow cytometry Methods 0.000 description 15
- 239000000463 material Substances 0.000 description 15
- 238000005096 rolling process Methods 0.000 description 15
- 206010063837 Reperfusion injury Diseases 0.000 description 13
- 230000035605 chemotaxis Effects 0.000 description 13
- 101000609767 Dromaius novaehollandiae Ovalbumin Proteins 0.000 description 12
- 230000007423 decrease Effects 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 210000004072 lung Anatomy 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 201000006417 multiple sclerosis Diseases 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 230000002519 immonomodulatory effect Effects 0.000 description 11
- 230000002107 myocardial effect Effects 0.000 description 11
- 208000006011 Stroke Diseases 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 210000003205 muscle Anatomy 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 9
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 9
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 239000002975 chemoattractant Substances 0.000 description 9
- 229960003677 chloroquine Drugs 0.000 description 9
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 9
- 239000012530 fluid Substances 0.000 description 9
- 208000008423 pleurisy Diseases 0.000 description 9
- 102100025470 Carcinoembryonic antigen-related cell adhesion molecule 8 Human genes 0.000 description 8
- 101000914320 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 8 Proteins 0.000 description 8
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 8
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 208000029028 brain injury Diseases 0.000 description 8
- 206010008118 cerebral infarction Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000008595 infiltration Effects 0.000 description 8
- 238000001764 infiltration Methods 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 210000003657 middle cerebral artery Anatomy 0.000 description 8
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 7
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 7
- 206010022680 Intestinal ischaemia Diseases 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 238000009825 accumulation Methods 0.000 description 7
- 239000000443 aerosol Substances 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 7
- 238000012937 correction Methods 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 208000037906 ischaemic injury Diseases 0.000 description 7
- 230000002530 ischemic preconditioning effect Effects 0.000 description 7
- 230000004224 protection Effects 0.000 description 7
- 210000000813 small intestine Anatomy 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 201000006474 Brain Ischemia Diseases 0.000 description 6
- 206010008120 Cerebral ischaemia Diseases 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 6
- 208000037883 airway inflammation Diseases 0.000 description 6
- 230000036770 blood supply Effects 0.000 description 6
- 230000006931 brain damage Effects 0.000 description 6
- 231100000874 brain damage Toxicity 0.000 description 6
- 230000001054 cortical effect Effects 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 238000012771 intravital microscopy Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 6
- 230000010411 postconditioning Effects 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 238000011552 rat model Methods 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 6
- 206010028851 Necrosis Diseases 0.000 description 5
- 102100040247 Tumor necrosis factor Human genes 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 210000003979 eosinophil Anatomy 0.000 description 5
- 210000004969 inflammatory cell Anatomy 0.000 description 5
- 230000028709 inflammatory response Effects 0.000 description 5
- 230000017074 necrotic cell death Effects 0.000 description 5
- 230000008506 pathogenesis Effects 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- 229940071127 thioglycolate Drugs 0.000 description 5
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 5
- 230000002861 ventricular Effects 0.000 description 5
- 210000000264 venule Anatomy 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 108020000411 Toll-like receptor Proteins 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 210000004413 cardiac myocyte Anatomy 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 230000003399 chemotactic effect Effects 0.000 description 4
- 238000011284 combination treatment Methods 0.000 description 4
- 230000003750 conditioning effect Effects 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 230000003511 endothelial effect Effects 0.000 description 4
- 210000003038 endothelium Anatomy 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 210000000416 exudates and transudate Anatomy 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 230000010413 ischemic postconditioning Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- ZBJWWKFMHOAPNS-UHFFFAOYSA-N loretin Chemical compound C1=CN=C2C(O)=C(I)C=C(S(O)(=O)=O)C2=C1 ZBJWWKFMHOAPNS-UHFFFAOYSA-N 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 208000031225 myocardial ischemia Diseases 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 210000003281 pleural cavity Anatomy 0.000 description 4
- -1 polyethylene Polymers 0.000 description 4
- 238000002203 pretreatment Methods 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 238000007492 two-way ANOVA Methods 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 238000009423 ventilation Methods 0.000 description 4
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 4
- 208000032382 Ischaemic stroke Diseases 0.000 description 3
- 108010057466 NF-kappa B Proteins 0.000 description 3
- 102000003945 NF-kappa B Human genes 0.000 description 3
- 108010058846 Ovalbumin Proteins 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 102000002689 Toll-like receptor Human genes 0.000 description 3
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 230000003293 cardioprotective effect Effects 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 210000005240 left ventricle Anatomy 0.000 description 3
- 231100000518 lethal Toxicity 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000005244 lower chamber Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000001550 testis Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- FQYRLEXKXQRZDH-UHFFFAOYSA-N 4-aminoquinoline Chemical compound C1=CC=C2C(N)=CC=NC2=C1 FQYRLEXKXQRZDH-UHFFFAOYSA-N 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- RZZPDXZPRHQOCG-OJAKKHQRSA-O CDP-choline(1+) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-O 0.000 description 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- 102000009410 Chemokine receptor Human genes 0.000 description 2
- 108050000299 Chemokine receptor Proteins 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010015866 Extravasation Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 2
- 206010024264 Lethargy Diseases 0.000 description 2
- 101710098610 Leukocyte surface antigen CD47 Proteins 0.000 description 2
- 229930184725 Lipoxin Natural products 0.000 description 2
- 208000004535 Mesenteric Ischemia Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000004721 adaptive immunity Effects 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 201000009961 allergic asthma Diseases 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 2
- 230000005961 cardioprotection Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000010205 computational analysis Methods 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000002222 downregulating effect Effects 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 231100000318 excitotoxic Toxicity 0.000 description 2
- 230000003492 excitotoxic effect Effects 0.000 description 2
- 230000036251 extravasation Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 208000008384 ileus Diseases 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 229940039412 ketalar Drugs 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 150000002639 lipoxins Chemical class 0.000 description 2
- 239000002932 luster Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000003622 mature neutrocyte Anatomy 0.000 description 2
- 210000003975 mesenteric artery Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 210000003061 neural cell Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 230000004112 neuroprotection Effects 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000008816 organ damage Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000010118 platelet activation Effects 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 210000004706 scrotum Anatomy 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical group OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- NALREUIWICQLPS-UHFFFAOYSA-N 7-imino-n,n-dimethylphenothiazin-3-amine;hydrochloride Chemical compound [Cl-].C1=C(N)C=C2SC3=CC(=[N+](C)C)C=CC3=NC2=C1 NALREUIWICQLPS-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 108010059108 CD18 Antigens Proteins 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000022306 Cerebral injury Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010149 Complicated fracture Diseases 0.000 description 1
- 206010011086 Coronary artery occlusion Diseases 0.000 description 1
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 1
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102100040611 Endothelin receptor type B Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 102000008015 Hemeproteins Human genes 0.000 description 1
- 108010089792 Hemeproteins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 1
- 101001017969 Homo sapiens Leukotriene B4 receptor 2 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010058558 Hypoperfusion Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 239000012839 Krebs-Henseleit buffer Substances 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102100033375 Leukotriene B4 receptor 2 Human genes 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- 108020002496 Lysophospholipase Proteins 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- 229920004011 Macrolon® Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000183024 Populus tremula Species 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010063897 Renal ischaemia Diseases 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 241000826860 Trapezium Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000035868 Vascular inflammations Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- IXYNFLOLUBKHQU-FZCWJHTDSA-N [(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-(hydroxymethyl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl] hydrogen phosphate Chemical compound Cc1cn([C@H]2C[C@H](OP(O)(=O)OC[C@H]3O[C@H](C[C@@H]3OP(O)(=O)OC[C@H]3O[C@H](C[C@@H]3OP(O)(=O)OC[C@H]3O[C@H](C[C@@H]3OP(O)(=O)OC[C@H]3O[C@H](C[C@@H]3OP(O)(=S)OC[C@H]3O[C@H](C[C@@H]3OP(O)(=S)OC[C@H]3O[C@H](C[C@@H]3OP(O)(=S)OC[C@H]3O[C@H](C[C@@H]3O)n3ccc(N)nc3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)[C@@H](COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=S)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=S)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=S)O[C@H]3C[C@@H](O[C@@H]3CO)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c3nc(N)[nH]c4=O)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cnc4c3nc(N)[nH]c4=O)O2)c(=O)[nH]c1=O IXYNFLOLUBKHQU-FZCWJHTDSA-N 0.000 description 1
- OMOVVBIIQSXZSZ-UHFFFAOYSA-N [6-(4-acetyloxy-5,9a-dimethyl-2,7-dioxo-4,5a,6,9-tetrahydro-3h-pyrano[3,4-b]oxepin-5-yl)-5-formyloxy-3-(furan-3-yl)-3a-methyl-7-methylidene-1a,2,3,4,5,6-hexahydroindeno[1,7a-b]oxiren-4-yl] 2-hydroxy-3-methylpentanoate Chemical compound CC12C(OC(=O)C(O)C(C)CC)C(OC=O)C(C3(C)C(CC(=O)OC4(C)COC(=O)CC43)OC(C)=O)C(=C)C32OC3CC1C=1C=COC=1 OMOVVBIIQSXZSZ-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000001964 calcium overload Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000036722 left ventricular developed pressure Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000006679 metabolic signaling pathway Effects 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 208000037891 myocardial injury Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100001160 nonlethal Toxicity 0.000 description 1
- NJPPVKZQTLUDBO-UHFFFAOYSA-N novaluron Chemical compound C1=C(Cl)C(OC(F)(F)C(OC(F)(F)F)F)=CC=C1NC(=O)NC(=O)C1=C(F)C=CC=C1F NJPPVKZQTLUDBO-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 235000021401 pellet diet Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000013146 percutaneous coronary intervention Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- WPPDXAHGCGPUPK-UHFFFAOYSA-N red 2 Chemical compound C1=CC=CC=C1C(C1=CC=CC=C11)=C(C=2C=3C4=CC=C5C6=CC=C7C8=C(C=9C=CC=CC=9)C9=CC=CC=C9C(C=9C=CC=CC=9)=C8C8=CC=C(C6=C87)C(C=35)=CC=2)C4=C1C1=CC=CC=C1 WPPDXAHGCGPUPK-UHFFFAOYSA-N 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000007727 signaling mechanism Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11128408P | 2008-11-04 | 2008-11-04 | |
| SE0802338 | 2008-11-04 | ||
| EP09825058.2A EP2342341B1 (en) | 2008-11-04 | 2009-10-28 | Compounds and methods for reducing the recruitment and/or migration of polymorphonuclear cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2806028T3 true DK2806028T3 (en) | 2017-10-09 |
Family
ID=42153087
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14154643.2T DK2806028T3 (en) | 2008-11-04 | 2009-10-28 | RELATIONS AND PROCEDURES FOR REDUCING RECRUITMENT OR MIGRATION OF POLYMORPHNUCLEAR CELLS |
| DK09825058.2T DK2342341T3 (da) | 2008-11-04 | 2009-10-28 | Forbindelser og fremgangsmåder til at reducere rekruttering og/eller migration af polymorfnukleare celler |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09825058.2T DK2342341T3 (da) | 2008-11-04 | 2009-10-28 | Forbindelser og fremgangsmåder til at reducere rekruttering og/eller migration af polymorfnukleare celler |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8877724B2 (enExample) |
| EP (2) | EP2806028B1 (enExample) |
| JP (1) | JP5749651B2 (enExample) |
| AU (1) | AU2009311748B2 (enExample) |
| CA (1) | CA2778938C (enExample) |
| DK (2) | DK2806028T3 (enExample) |
| ES (2) | ES2464731T3 (enExample) |
| HR (1) | HRP20171360T1 (enExample) |
| LT (1) | LT2806028T (enExample) |
| PL (1) | PL2806028T3 (enExample) |
| WO (1) | WO2010053430A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2560782T3 (es) * | 2008-11-04 | 2016-02-22 | Index Pharmaceuticals Ab | Compuestos y métodos para el tratamiento de enfermedades inflamatorias del SNC |
| EP2468866A1 (en) | 2010-12-21 | 2012-06-27 | Index Pharmaceuticals AB | Biologically active oligonucleotides capable of modulating the immune system |
| CA2859698C (en) | 2010-12-21 | 2021-03-02 | Index Pharmaceuticals Ab | Methods for identifying biologically active oligonucleotides capable of modulating the immune system |
| EP2468867A1 (en) | 2010-12-21 | 2012-06-27 | Index Pharmaceuticals AB | Methods for identifying biologically active oligonucleotides capable of modulating the immune system |
| WO2012084991A1 (en) | 2010-12-21 | 2012-06-28 | Index Pharmaceuticals Ab | Biologically active oligonucleotides capable of modulating the immune system ii |
| US9873878B2 (en) * | 2015-03-30 | 2018-01-23 | University Of Louisville Research Foundation, Inc. | Compositions and methods for use in treating silicosis and lung cancer |
| US20180193270A1 (en) | 2016-11-29 | 2018-07-12 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
| JP2021131228A (ja) * | 2018-04-27 | 2021-09-09 | 国立大学法人 東京大学 | 難治性喘息の予防又は治療剤をスクリーニングする方法、及び難治性喘息の予防又は治療剤 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6172208B1 (en) * | 1992-07-06 | 2001-01-09 | Genzyme Corporation | Oligonucleotides modified with conjugate groups |
| SE9602300D0 (sv) * | 1996-06-11 | 1996-06-11 | Karolinska Innovations Ab | New composition and methods |
| ES2246230T3 (es) | 1999-03-18 | 2006-02-16 | The Brigham And Women's Hospital, Inc. | Compuestos de lipoxina y su utilizacion. |
| US6489311B1 (en) * | 2000-05-02 | 2002-12-03 | Charlotte-Mecklenburg Hospital Authoirty | Method for the prevention of apoptosis |
| JP2006527741A (ja) * | 2003-06-19 | 2006-12-07 | シーティーティー キャンサー ターゲッティング テクノロジーズ オイ | 細胞遊走の阻害剤 |
| SE0400399D0 (sv) | 2004-02-20 | 2004-02-20 | Index Pharmaceuticals Ab | Methods and compositions for the treatment or prevention of secondary ischemic injury |
| WO2007030580A2 (en) * | 2005-09-09 | 2007-03-15 | Oregon Health & Science University | Neuroprotectants |
| WO2007030581A2 (en) | 2005-09-09 | 2007-03-15 | Oregon Health & Science University | Neuroprotectants |
| US8309529B2 (en) | 2007-05-04 | 2012-11-13 | Index Pharmaceuticals Ab | Tumour growth inhibitory compounds and methods of their use |
| ES2560782T3 (es) | 2008-11-04 | 2016-02-22 | Index Pharmaceuticals Ab | Compuestos y métodos para el tratamiento de enfermedades inflamatorias del SNC |
| US20110280934A1 (en) | 2008-11-04 | 2011-11-17 | Asa Karlsson | Increased Expression of Specific Antigens |
-
2009
- 2009-10-28 ES ES09825058.2T patent/ES2464731T3/es active Active
- 2009-10-28 WO PCT/SE2009/051227 patent/WO2010053430A1/en not_active Ceased
- 2009-10-28 ES ES14154643.2T patent/ES2641751T3/es active Active
- 2009-10-28 EP EP14154643.2A patent/EP2806028B1/en active Active
- 2009-10-28 DK DK14154643.2T patent/DK2806028T3/en active
- 2009-10-28 DK DK09825058.2T patent/DK2342341T3/da active
- 2009-10-28 AU AU2009311748A patent/AU2009311748B2/en not_active Ceased
- 2009-10-28 LT LTEP14154643.2T patent/LT2806028T/lt unknown
- 2009-10-28 CA CA2778938A patent/CA2778938C/en active Active
- 2009-10-28 US US13/127,217 patent/US8877724B2/en active Active
- 2009-10-28 JP JP2011535537A patent/JP5749651B2/ja not_active Expired - Fee Related
- 2009-10-28 PL PL14154643T patent/PL2806028T3/pl unknown
- 2009-10-28 EP EP09825058.2A patent/EP2342341B1/en active Active
-
2014
- 2014-10-10 US US14/512,036 patent/US10046006B2/en active Active
-
2017
- 2017-09-11 HR HRP20171360TT patent/HRP20171360T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010053430A1 (en) | 2010-05-14 |
| AU2009311748A1 (en) | 2010-05-14 |
| EP2342341A1 (en) | 2011-07-13 |
| AU2009311748B2 (en) | 2014-08-21 |
| EP2342341A4 (en) | 2013-01-09 |
| US10046006B2 (en) | 2018-08-14 |
| JP5749651B2 (ja) | 2015-07-15 |
| US20110301225A1 (en) | 2011-12-08 |
| US20150099799A1 (en) | 2015-04-09 |
| CA2778938C (en) | 2019-07-02 |
| EP2806028A2 (en) | 2014-11-26 |
| DK2342341T3 (da) | 2014-05-12 |
| LT2806028T (lt) | 2017-12-11 |
| US8877724B2 (en) | 2014-11-04 |
| EP2806028A3 (en) | 2015-03-11 |
| EP2342341B1 (en) | 2014-03-05 |
| HRP20171360T1 (hr) | 2017-11-03 |
| ES2464731T3 (es) | 2014-06-03 |
| PL2806028T3 (pl) | 2017-11-30 |
| JP2012507307A (ja) | 2012-03-29 |
| EP2806028B1 (en) | 2017-07-12 |
| ES2641751T3 (es) | 2017-11-13 |
| CA2778938A1 (en) | 2010-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10046006B2 (en) | Compounds and methods for reducing the recruitment and/or migration of polymorphonuclear cells | |
| Wu et al. | Transforming growth factor β-1 stimulates profibrotic epithelial signaling to activate pericyte-myofibroblast transition in obstructive kidney fibrosis | |
| US20160122758A1 (en) | Agents for downregulation of the activity and/or amount of bcl-xl and/or bcl-w | |
| Guan et al. | Dysregulated chemokine signaling in cystic fibrosis lung disease: a potential therapeutic target | |
| US20140271860A1 (en) | Methods of Treating Colorectal Cancer | |
| EP2970419A1 (en) | Methods of treating colorectal cancer | |
| CN114288288A (zh) | 一种gsdmd抑制剂及在制备神经免疫疾病、炎症感染疾病防治药物中的应用 | |
| US9610331B2 (en) | Methods for hematopoietic precursor mobilization | |
| CN115551520A (zh) | 败血症和高细胞因子血症的治疗 | |
| CN105555279B (zh) | 用于治疗脓毒症的MicroRNA抑制 | |
| RU2663100C2 (ru) | Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний | |
| EP2207555A1 (en) | Novel compounds for the treatment or alleviation of edema, and methods for their use | |
| Han et al. | Mitochondria are essential for antibacterial extracellular trap formation mediated by zymosan in hemocytes of Ruditapes philippinarum | |
| US20030119776A1 (en) | Modulation of Fas and FasL expression | |
| DK2350283T3 (en) | RELATIONS AND PROCEDURES FOR THE TREATMENT OF INFLAMMATORY DISEASES IN THE CENTRAL NERVOUS SYSTEM | |
| WO2005080568A1 (en) | Methods and compositions for treatment or prevention of secondary ischemic injury | |
| WO2015113511A1 (zh) | 串联表达的siRNA及其在治疗慢性淋巴细胞白血病中的应用 | |
| US20220119819A1 (en) | Formulation | |
| Xin et al. | Aberrant Neuronal Excitation in Acute Ischemic Stroke Exacerbates the Neuronal Injury by Activating Local Microglia and Neuron Through Unique Small Extracellular Vesicles | |
| KR20250136380A (ko) | 감염 질환을 치료하기 위한 압타머 및 비타민 c 복합체의 용도 | |
| JP5744560B2 (ja) | ファスシン（Ｆａｓｃｉｎ）遺伝子の働きを抑える短鎖ＲＮＡを含有する癌の予防、治療剤 | |
| CN116751856A (zh) | Peli1基因在制备慢性髓系白血病诊断试剂及治疗慢性髓系白血病药物中的应用 | |
| CN113712963A (zh) | Bet抑制剂bms-986158在制备抗艾滋病的药物中的应用 | |
| KR20100095713A (ko) | Ｔｈ1 면역반응을 유발하는 ＣｐＧ 올리고디옥시뉴클레오타이드 및 그 제작 방법 |